MT Højgaard Holding A/S
On 23 November 2020, MT Højgaard Holding A/S announced that a share buy-back programme of an aggregated price of up to DKK 15,000,000 was launched with the purpose to meet obligations arising from the company’s share-based incentive programme.
The share buy-back programme is executed pursuant to the so-called "Safe Harbour" provisions in Regulation (EU) No. 596/2014 of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016. The programme will end no later than on 30 September 2021.
The following transactions have been executed from 15 February to 19 February 2021:
Number of shares | Average purchase price (DKK) | Transaction value (DKK) | |
Accumulated, last announcement | 30,320 | 166.77 | 5,056,328 |
15 February 2021 16 February 2021 17 February 2021 18 February 2021 19 February 2021 | 400 400 500 400 400 | 178.80 178.45 180.40 183.75 178.00 | 71,520 71,380 90,200 73,500 71,200 |
Accumulated under the programme | 32,420 | 5,434,128 |
A detailed overview of transactions executed during the period 15 February to 19 February 2021 is attached to this announcement.
Following the above transactions, MT Højgaard Holding A/S owns a total of 32,420 treasury shares, corresponding to 0.416% of the company’s total share capital.
Contact: CFO Martin Stig Solberg may be contacted by phone on +45 2270 9365
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novo Nordisk A/S17.9.2025 23:05:02 CEST | Press release
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Biogen Inc.17.9.2025 22:30:05 CEST | Press release
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Atico Mining Corporation17.9.2025 22:30:00 CEST | Press release
Atico Signs the Investment Protection Agreement with Government of Ecuador for its La Plata Project
Frontline plc.17.9.2025 22:06:51 CEST | Press release
FRO – Filing of Half Yearly Report
VCI Global Limited17.9.2025 21:00:00 CEST | Press release
VCI Global Initiates Rescission and Cancellation of Shares from QuantGold Transaction, Tightening Capital Structure Following Reverse Split
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom